ARAsius T. A. Rayen

Asius T. A. Rayen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Asius T. A. Rayen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and Experiential Outcomes of Photobiomodulation Therapy as a Treatment for Fibromyalgia: A Scoping Review in Response to NICE Recommendations

    by Bethany C. Fitzmaurice, James Carroll, Asius T. A. Rayen, Nicola R. Heneghan, Andrew A. Soundy

    (1) Background: There has been a recent growth in evidence regarding the use, value and impact of photobiomodulation therapy for individuals with fibromyalgia. However, the nature of the evidence has, to the best of the authors’ knowledge, not been presented within a scoping review. The objective of this work is to reveal the nature of the evidence, gaps in the evidence, and a map of the evidence considering photobiomodulation therapy against established policy guidelines; (2) Methods: A scoping review was undertaken considering all academic research that has examined the experiences and impact of photobiomodulation therapy on individuals with fibromyalgia; (3) Results: Our results highlight that, indeed, there is plentiful data available to address a high proportion of the concerns portrayed by the National Institute for Healthcare and Excellence. Outcome measures are wide-ranging, albeit demonstrating heterogeneity, and the results are extremely promising; (4) Conclusion: Based on the current evidence, the United Kingdom’s ‘standard of care’ for fibromyalgia needs to be ascertained, and stringent cost-effectiveness data needs to be collected and presented to governing bodies with the aim of integrating recommendations into future healthcare guidelines.

  • Open Access

    Clinical and Experiential Outcomes of Photobiomodulation Therapy as a Treatment for Fibromyalgia: A Scoping Review in Response to NICE Recommendations

    by Bethany C. Fitzmaurice, James Carroll, Asius T.A. Rayen, Nicola R. Heneghan, Andrew A. Soundy

    There is a recent growth in evidence around the use, value and impact of photobiomodulation therapy for individuals with fibromyalgia. However, the nature of the evidence, has, to the best of the authors’ knowledge not been presented within a scoping review. The objective of this work is to reveal the nature of the evidence, gaps in the evidence and map of the evidence considering photobiomodulation therapy against established policy guidelines. A scoping review was undertaken considering all academic evidence that has examined the experiences and impact of photobiomodulation therapy on individuals with fibromyalgia. Our results highlight that indeed there is plentiful data available to address a high proportion of concerns portrayed by the National Institute for Healthcare and Excellence. Outcome measures are wide ranging, albeit demonstrating heterogeneity, and results are extremely promising. Based on the current evidence base, the United Kingdom ‘standard of care’ for fibromyalgia needs to be ascertained, and stringent cost-effectiveness data needs to be collected and presented to governing bodies with the aim of integrating recommendations into future healthcare guidelines.

  • Open Access

    Whole-Body Photobiomodulation Therapy Propels the Fibromyalgia Patient into the Recomposition Phase: A Reflexive Thematic Analysis

    by Bethany C. Fitzmaurice, Rebecca L. Grenfell, Nicola R. Heneghan, Asius T. A. Rayen, Andrew A. Soundy

    Background: Recent evidence has identified great promise for the novel whole-body photobiomodulation therapy (PBMT) for individuals with fibromyalgia (FM). However, currently no evidence has documented the experiences of participants. The objective of this study was to qualitatively assess treatment experience and response in a group of participants with FM undergoing a course of whole-body PBMT. Methods: An interpretive hermeneutic phenomenological study situated within the worldview of pragmatism was undertaken. A convenience sample of individuals with FM were included if they had undertaken a novel 6-week trial of PBMT. Individuals undertook semi-structured interviews exploring treatment experience and multidimensional treatment responses during Week 3 and Week 6. Results: Sixteen trial participants (47.3 ± 10.9 years) took part in this study. The analysis produced three overarching themes that were previously identified from a baseline study (namely, ‘Body Structure & Function’, ‘Activities & Participation’, and ‘Environment’) with an additional five sub-themes that highlighted the intervention experience. Subsequently, four important processes were observed and identified: increased motivation; feeling proud; improved confidence; feeling like ‘old self’. This ultimately culminated in the identification of a positive spiral, which we have termed ‘recomposition’. Conclusions: We believe our study is the first in the field of chronic pain management to utilise qualitative methodology to directly assess the acceptability and efficacy of a specific medical intervention in a clinical trial, and the first study to qualitatively assess whole-body PBMT experience. The findings are compelling and warrant further work to support the introduction of this device into the National Health Service (NHS).


  • Open Access

    The Fibromyalgia Decomposition Phenomenon: A Reflexive Thematic Analysis

    by Bethany C. Fitzmaurice, Rebecca L. Grenfell, Nicola R. Heneghan, Asius T. A. Rayen, Andrew A. Soundy

    Research is needed that can provide an illustration of the different biopsychosocial and environmental experiences of people with fibromyalgia to consider how healthcare professionals can best engage with the challenges that are faced. Qualitative research is well-positioned to do this. The current study used interpretive hermeneutic phenomenology situated within a pragmatic worldview, the aim being to obtain a deeper exploration of the fibromyalgia experience prior to commencing a novel intervention. A purposive sample of individuals with fibromyalgia were selected to undertake a single interview. The interviews were analysed using a thematic analysis. The themes identified key processes of the experience. A total of 16 participants (mean age: 47.1 years) took part. Three themes and 15 sub-themes were identified, together with a process linking different experiences together. The research from this small cohort provides a clear identification of multiple components influencing the experience of fibromyalgia and the decisions around lifestyle and choices made. From this, a novel decomposition/recomposition spiral has been identified, which will benefit patients and healthcare professionals alike. An earlier diagnosis and, thus, earlier and broader treatment options can help to improve functional outcomes.


  • Open Access

    Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

    by Bethany C. Fitzmaurice, Nicola R. Heneghan, Asius T. A. Rayen, Rebecca L. Grenfell, Andrew A. Soundy

    Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. A single-arm feasibility study was conducted in accordance with CONSORT (Consolidated Standards of Reporting Trials) guidelines. A non-probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and twenty-one trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT (outcomes measures in rheumatological clinical trials) domains, utilising a combination of participant-reported and performance-based outcome measures. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM-specific quality of life at 24 weeks remained improved compared with baseline scores. The findings provided evidence to support a full-scale trial and showed promise regarding potential efficacy of this novel non-invasive treatment in an FM population.